Steven W Lane

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6247957/publications.pdf

Version: 2024-02-01

116 papers	5,869 citations	126907 33 h-index	76900 74 g-index
117 all docs	117 docs citations	117 times ranked	11756 citing authors

#	Article	IF	Citations
1	Exit from dormancy provokes DNA-damage-induced attrition in haematopoietic stem cells. Nature, 2015, 520, 549-552.	27.8	498
2	Modulating the stem cell niche for tissue regeneration. Nature Biotechnology, 2014, 32, 795-803.	17.5	492
3	BET inhibitor resistance emerges from leukaemia stem cells. Nature, 2015, 525, 538-542.	27.8	441
4	The leukemic stem cell niche: current concepts and therapeutic opportunities. Blood, 2009, 114, 1150-1157.	1.4	422
5	Musashi-2 regulates normal hematopoiesis and promotes aggressive myeloid leukemia. Nature Medicine, 2010, 16, 903-908.	30.7	338
6	Physiological Jak2V617F Expression Causes a Lethal Myeloproliferative Neoplasm with Differential Effects on Hematopoietic Stem and Progenitor Cells. Cancer Cell, 2010, 17, 584-596.	16.8	324
7	AKT/FOXO Signaling Enforces Reversible Differentiation Blockade in Myeloid Leukemias. Cell, 2011, 146, 697-708.	28.9	232
8	Genetic and Pharmacologic Inhibition of Î²-Catenin Targets Imatinib-Resistant Leukemia Stem Cells in CML. Cell Stem Cell, 2012, 10, 412-424.	11.1	209
9	mTOR Complex 1 Plays Critical Roles in Hematopoiesis and Pten-Loss-Evoked Leukemogenesis. Cell Stem Cell, 2012, 11, 429-439.	11.1	172
10	Oncogenic JAK2 ^{V617F} causes PD-L1 expression, mediating immune escape in myeloproliferative neoplasms. Science Translational Medicine, 2018, 10, .	12.4	166
11	Deciphering Hematopoietic Stem Cells in Their Niches: A Critical Appraisal of Genetic Models, Lineage Tracing, and Imaging Strategies. Cell Stem Cell, 2013, 13, 520-533.	11.1	148
12	Depletion of Jak2V617F myeloproliferative neoplasm-propagating stem cells by interferon-Î± in a murine model of polycythemia vera. Blood, 2013, 121, 3692-3702.	1.4	140
13	Differential niche and Wnt requirements during acute myeloid leukemia progression. Blood, 2011, 118, 2849-2856.	1.4	139
14	Managing haematology and oncology patients during the <scp>COVID</scp> â€19 pandemic: interim consensus guidance. Medical Journal of Australia, 2020, 212, 481-489.	1.7	107
15	Induced Regulatory T Cells Promote Tolerance When Stabilized by Rapamycin and IL-2 In Vivo. Journal of Immunology, 2013, 191, 5291-5303.	0.8	101
16	Tc17 cells are a proinflammatory, plastic lineage of pathogenic CD8+ T cells that induce GVHD without antileukemic effects. Blood, 2015, 126, 1609-1620.	1.4	98
17	CD155 loss enhances tumor suppression via combined host and tumor-intrinsic mechanisms. Journal of Clinical Investigation, 2018, 128, 2613-2625.	8.2	91
18	Harnessing the immune system in acute myeloid leukaemia. Critical Reviews in Oncology/Hematology, 2016, 103, 62-77.	4.4	90

#	Article	IF	Citations
19	Splicing factor YBX1 mediates persistence of JAK2-mutated neoplasms. Nature, 2020, 588, 157-163.	27.8	90
20	The Apcmin mouse has altered hematopoietic stem cell function and provides a model for MPD/MDS. Blood, 2010, 115, 3489-3497.	1.4	88
21	Recipient mucosal-associated invariant T cells control GVHD within the colon. Journal of Clinical Investigation, 2018, 128, 1919-1936.	8.2	78
22	Intact TP-53 function is essential for sustaining durable responses to BH3-mimetic drugs in leukemias. Blood, 2021, 137, 2721-2735.	1.4	75
23	Telomerase Inhibition Effectively Targets Mouse and Human AML Stem Cells and Delays Relapse following Chemotherapy. Cell Stem Cell, 2014, 15, 775-790.	11.1	74
24	Leukemia stem cells. Seminars in Cancer Biology, 2010, 20, 71-76.	9.6	65
25	Distinct roles for long-term hematopoietic stem cells and erythroid precursor cells in a murine model of Jak2V617F-mediated polycythemia vera. Blood, 2012, 120, 166-172.	1.4	65
26	Global prevalence of carbapenem resistance in neutropenic patients and association with mortality and carbapenem use: systematic review and meta-analysis. Journal of Antimicrobial Chemotherapy, 2016, 72, dkw459.	3.0	57
27	Jak2V617F and Dnmt3a loss cooperate to induce myelofibrosis through activated enhancer-driven inflammation. Blood, 2018, 132, 2707-2721.	1.4	56
28	The impact of age, NPM1mut, and FLT3ITD allelic ratio in patients with acute myeloid leukemia. Blood, 2018, 131, 1148-1153.	1.4	53
29	A â‰¥1 log rise in RQ-PCR transcript levels defines molecular relapse in core binding factor acute myeloid leukemia and predicts subsequent morphologic relapse. Leukemia and Lymphoma, 2008, 49, 517-523.	1.3	48
30	The cell fate determinant Llgl1 influences HSC fitness and prognosis in AML. Journal of Experimental Medicine, 2013, 210, 15-22.	8.5	47
31	CDX2-driven leukemogenesis involves KLF4 repression and deregulated PPARÎ³ signaling. Journal of Clinical Investigation, 2013, 123, 299-314.	8.2	47
32	Autophagy-dependent regulatory T cells are critical for the control of graft-versus-host disease. JCI Insight, 2016, 1, e86850.	5.0	43
33	Transcriptome dynamics of CD4+ T cells during malaria maps gradual transit from effector to memory. Nature Immunology, 2020, 21, 1597-1610.	14.5	43
34	Autophagy is required for stem cell mobilization by G-CSF. Blood, 2015, 125, 2933-2936.	1.4	36
35	Type I Interferons Suppress Anti-parasitic Immunity and Can Be Targeted to Improve Treatment of Visceral Leishmaniasis. Cell Reports, 2020, 30, 2512-2525.e9.	6.4	34
36	Myeloproliferative Neoplasm Animal Models. Hematology/Oncology Clinics of North America, 2012, 26, 1065-1081.	2.2	33

#	Article	IF	Citations
37	GVHD prevents NK-cellâ€“dependent leukemia and virus-specific innate immunity. Blood, 2017, 129, 630-642.	1.4	32
38	The Rac GTPase effector p21-activated kinase is essential for hematopoietic stem/progenitor cell migration and engraftment. Blood, 2013, 121, 2474-2482.	1.4	31
39	IFN Regulatory Factor 3 Balances Th1 and T Follicular Helper Immunity during Nonlethal Blood-Stage Plasmodium Infection. Journal of Immunology, 2018, 200, 1443-1456.	0.8	31
40	Epo-induced erythroid maturation is dependent on PlcÎ³1 signaling. Cell Death and Differentiation, 2015, 22, 974-985.	11.2	30
41	Distinct effects of ruxolitinib and interferon-alpha on murine JAK2V617F myeloproliferative neoplasm hematopoietic stem cell populations. Leukemia, 2020, 34, 1075-1089.	7.2	29
42	MPN: The Molecular Drivers of Disease Initiation, Progression and Transformation and their Effect on Treatment. Cells, 2020, 9, 1901.	4.1	27
43	WT1 expression as a marker of minimal residual disease predicts outcome in acute myeloid leukemia when measured post-consolidation. Leukemia Research, 2012, 36, 453-458.	0.8	26
44	Leukaemia cutis in atypical chronic myeloid leukaemia with a t(9;22) (p24;q11.2) leading to BCRâ€JAK2 fusion. British Journal of Haematology, 2008, 142, 503-503.	2.5	24
45	Safety and efficacy of pegfilgrastim compared to granulocyte colony stimulating factor (G-CSF) supporting a dose-intensive, rapidly cycling anti-metabolite containing chemotherapy regimen (Hyper-CVAD) for lymphoid malignancy. Leukemia and Lymphoma, 2006, 47, 1813-1817.	1.3	22
46	Rac signaling in osteoblastic cells is required for normal bone development but is dispensable for hematopoietic development. Blood, 2012, 119, 736-744.	1.4	22
47	IFN-Î» therapy prevents severe gastrointestinal graft-versus-host disease. Blood, 2021, 138, 722-737.	1.4	21
48	Flt-3L Expansion of Recipient CD8Î±+ Dendritic Cells Deletes Alloreactive Donor T Cells and Represents an Alternative to Posttransplant Cyclophosphamide for the Prevention of GVHD. Clinical Cancer Research, 2018, 24, 1604-1616.	7.0	20
49	EphA2 Is a Therapy Target in EphA2-Positive Leukemias but Is Not Essential for Normal Hematopoiesis or Leukemia. PLoS ONE, 2015, 10, e0130692.	2.5	20
50	Palifermin-induced acanthosis nigricans. Internal Medicine Journal, 2007, 37, 417-418.	0.8	18
51	Ssb1 and Ssb2 cooperate to regulate mouse hematopoietic stem and progenitor cells by resolving replicative stress. Blood, 2017, 129, 2479-2492.	1.4	18
52	Valproic acid combined with cytosine arabinoside in elderly patients with acute myeloid leukemia has in vitro but limited clinical activity. Leukemia and Lymphoma, 2012, 53, 1077-1083.	1.3	16
53	PLCG1 is required for AML1-ETO leukemia stem cell self-renewal. Blood, 2022, 139, 1080-1097.	1.4	16
54	Prolonged haematological toxicity from the hyper-CVAD regimen: manifestations, frequency, and natural history in a cohort of 125 consecutive patients. Annals of Hematology, 2008, 87, 727-734.	1.8	15

#	Article	IF	Citations
55	Tolerance induction with gene-modified stem cells and immune-preserving conditioning in primed mice: restricting antigen to differentiated antigen-presenting cells permits efficacy. Blood, 2013, 121, 1049-1058.	1.4	15
56	Hematopoietic stem and progenitor cell-restricted Cdx2 expression induces transformation to myelodysplasia and acute leukemia. Nature Communications, 2020, 11, 3021.	12.8	15
57	Role of VAD in the initial treatment of multiple myeloma. Blood, 2005, 106, 3674-3675.	1.4	14
58	Murine Models of Myelofibrosis. Cancers, 2020, 12, 2381.	3.7	14
59	Bad to the bone. Blood, 2012, 119, 323-325.	1.4	13
60	Myeloid somatic mutation panel testing in myeloproliferative neoplasms. Pathology, 2021, 53, 339-348.	0.6	13
61	Epigenetic Activation of Plasmacytoid DCs Drives IFNAR-Dependent Therapeutic Differentiation of AML. Cancer Discovery, 2022, 12, 1560-1579.	9.4	13
62	Telomerase in hematologic malignancies. Current Opinion in Hematology, 2016, 23, 346-353.	2.5	12
63	Ssb2/Nabp1 is dispensable for thymic maturation, male fertility, and DNA repair in mice. FASEB Journal, 2015, 29, 3326-3334.	0.5	11
64	Pseudoaneurysm causing partial obliteration of the left atrium: Case report and review. Catheterization and Cardiovascular Diagnosis, 1996, 38, 83-86.	0.3	8
65	CNS Relapse in Acute Promyeloctyic Leukemia. Journal of Clinical Oncology, 2010, 28, e409-e411.	1.6	8
66	Acute myeloid leukemia stem cell function is preserved in the absence of autophagy. Haematologica, 2017, 102, e344-e347.	3.5	8
67	Recommendations for the use of pegylated interferonâ€Î± in the treatment of classical myeloproliferative neoplasms. Internal Medicine Journal, 2019, 49, 948-954.	0.8	7
68	Jak2V617F myeloproliferative neoplasm stem cells and interferon-alpha. Oncotarget, 2013, 4, 500-501.	1.8	7
69	Hereditary fibrinogen A alpha-chain amyloidosis. Pathology, 2006, 38, 380-382.	0.6	6
70	Intestinal pseudo-obstruction complicating multiple sclerosis. Internal Medicine Journal, 2005, 35, 191-192.	0.8	5
71	Jak2V617F driven myeloproliferative neoplasm occurs independently of interleukin-3 receptor beta common signaling. Haematologica, 2016, 101, e77-e80.	3.5	5
72	Conventional dendritic cells are required for the cross-presentation of leukemia-specific antigen in a model of AML relapse post-BMT. Bone Marrow Transplantation, 2018, 53, 800-803.	2.4	4

#	Article	IF	Citations
73	Optimizing DNA hypomethylating therapy in acute myeloid leukemia and myelodysplastic syndromes. BioEssays, 2021, 43, 2100125.	2.5	4
74	Better the cure you know: why patients with AML â‰¥60 years of age should be offered early allogeneic stem cell transplantation. Blood Advances, 2022, 6, 1619-1622.	5.2	4
75	A Phase-Ib/II Clinical Evaluation of Ponatinib in Combination with Azacitidine in FLT3-ITD and CBL-Mutant Acute Myeloid Leukemia (PON-AZA study). Blood, 2021, 138, 2350-2350.	1.4	4
76	Increased mortality with FLA compared with ADE chemotherapy in high-risk AML. Blood, 2006, 108, 3950-3951.	1.4	3
77	Hit the spleen, JAK!. Blood, 2014, 124, 2898-2900.	1.4	3
78	Hacking the stem cell niche. Blood, 2017, 129, 2951-2952.	1.4	2
79	Attenuated Acceleration to Leukemia after Ezh2ÂLoss in Nup98â€HoxD13 (NHD13) Myelodysplastic Syndrome. HemaSphere, 2019, 3, e277.	2.7	2
80	Small-Molecule Inhibition of PRMT5 Induces Translational Stress and p53 in JAK2V617F Mutant Myeloproliferative Neoplasms. Blood, 2018, 132, 53-53.	1.4	2
81	Integrated Molecular Analysis Identifies Replicative Stress As Sensitizer to Imetelstat Therapy in AML. Blood, 2017, 130, 798-798.	1.4	2
82	Panel-based gene testing in myelodysplastic/myeloproliferative neoplasm- overlap syndromes: Australasian Leukaemia and Lymphoma Group (ALLG) consensus statement. Pathology, 2022, , .	0.6	2
83	Analysis of telomerase target gene expression effects from murine models in patient cohorts by homology translation and random survival forest modeling. Genomics Data, 2016, 7, 275-280.	1.3	1
84	Evaluating Clonal Dominance in a Murine Knock-in Model of Jak2V617F MPN. Blood, 2011, 118, 614-614.	1.4	1
85	Autophagy Is Required For Long-Term Hematopoietic Stem Cell (HSC) Function and G-CSF-Induced HSC Mobilization. Blood, 2013, 122, 892-892.	1.4	1
86	Inhibition of Telomerase with Imetelstat Is Detrimental to Leukemia Stem Cells in Acute Myeloid Leukemia (AML). Blood, 2014, 124, 2322-2322.	1.4	1
87	Acute promyelocytic leukaemia with marked symptomatic hyperleucocytosis. British Journal of Haematology, 2019, 186, 649-649.	2.5	0
88	Inflammation in del(20q): a MST opportunity?. Blood, 2019, 134, 1685-1686.	1.4	0
89	Intravascular large Bâ€cell lymphoma presenting with extensive pulmonary embolism. British Journal of Haematology, 2021, 192, 677-677.	2.5	0
90	Protecting Our Most Vulnerable: Vaccine Responses in Patients With Blood Cancers. , 2021, 18, .		0

#	Article	IF	Citations
91	Leukemia Stem Cells. , 2012, , 85-103.		0
92	Mtor Complex 1 Plays Critical Roles in Hematopoiesis and Pten-Loss-Evoked Leukemogenesis. Blood, 2011, 118, 391-391.	1.4	0
93	Myeloid Leukemogenesis Driven by Aberrant CDX2 Expression Involves Transcriptional Repression of KLF4 and Deregulated PPARÎ³ Signaling. Blood, 2011, 118, 1355-1355.	1.4	0
94	Depletion of Jak2V617F MPN Stem Cells by IFNÎ± in a Murine Model of Polycythemia Vera. Blood, 2012, 120, 806-806.	1.4	0
95	HSC Exit From Dormancy Provokes De Novo DNA Damage, Leading To Bone Marrow Failure If Unresolved By The Fanconi Anemia Pathway. Blood, 2013, 122, 799-799.	1.4	0
96	Inhibition Of Telomerase Is a Novel and Effective Therapy In MLL-Rearranged Acute Myeloid Leukemia (AML). Blood, 2013, 122, 2887-2887.	1.4	0
97	IL3-Receptor Signaling Is Dispensable For The Generation and Maintenance Of Jak2V617F-Induced		

#	Article	IF	Citations
109	Gut Microbiome Diversity Influences Transplant Risk. , 2020, 17, .		0
110	Menin Inhibitors: A New Hope in MLL-Rearranged Leukemia?. , 2020, 17, .		0
111	Mapping Functional Susceptibilities in AML. , 2020, 17, .		0
112	Taking the Brakes Off Programmed Cell Death: Will It Work for AML in Older Patients?. , 2020, 17, .		0
113	A knockout combination for MPN stem cells. Journal of Experimental Medicine, 2021, 218, .	8.5	0
114	Targeting Control of Cell Cycle Enhances the Activity of Conventional Chemotherapy in Chemotherapy-Resistant Acute Myeloid Leukemia. Blood, 2021, 138, 2241-2241.	1.4	0
115	Oral Maintenance Therapy to Improve Survival in Older Patients With AML. , 2022, 19, .		0
116	Eltrombopag in Frontline Therapy for Severe Aplastic Anemia: A RACE Against Time. , 2022, 19, .		0